Drugs / IASO206
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07585071 | Jun → Dec 2026 expected | autoimmune hemolytic anemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 0 | NCT07322159 Comparator | Jan → Oct 2026 expected | refractory plasma cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-26 | Nanjing IASO Biotechnology Co., Ltd. | 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy Product IASO206 iasobio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IASO206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07585071 ↗ |